YAP promotes immune escape from tumors and tumor microenvironment immunosuppression through the modulation of immune-related factors, such as PD-L1 [13], CD24 [14], CXCL5 [15], etc. In addition to the YAP itself serving as an anti-cancer target, recent studies have also identified YAP-formed nuclear aggregates as potential targets for cancer therapy. The gene discussed is CD274; the disease is cancer.